» Articles » PMID: 31406511

A Review of the Diagnosis, Prevention, and Treatment Methods of Inflammatory Bowel Disease

Overview
Journal J Med Life
Specialty General Medicine
Date 2019 Aug 14
PMID 31406511
Citations 276
Authors
Affiliations
Soon will be listed here.
Abstract

Ulcerative colitis (UC) and Crohn's disease (CD) are classified as chronic inflammatory bowel diseases (IBD) which have similar symptoms and lead to digestive disorders and inflammation in the digestive system. The reason why they occur is still a mystery. A number of factors can be attributed to the prevalence of CD and UC, some of which include geographical location, inappropriate diet, genetics, and inappropriate immune response. Both diseases are more often diagnosed in urban areas compared to rural areas and both have their own challenges and side effects, but the patients can still have a good quality of life. Given the fact that the prevalence of this disease is higher at younger ages and that it disrupts half the life of the patient, it will, most likely, become a major health problem in the near future, even in developing countries. By reviewing valid scientific resources and evaluating new methods of addressing this disease, the present study aims to provide researchers and patients with new insights into this field and facilitate access to new treatments.

Citing Articles

Application of in combination with sulfasalazine in ulcerative colitis patients demonstrates significant effectiveness.

Yang C, Zhang S, Zhang R, Zhao Y, Yang D, Yang M World J Gastrointest Surg. 2025; 17(2):102342.

PMID: 40061979 PMC: 11885995. DOI: 10.4240/wjgs.v17.i2.102342.


A CRISPR mediated point-of-care assay for the detection of mucosal calprotectin in an animal model of ulcerative colitis.

Chia S, Guo T, Goldys E, Payne S, Duan W, Lovell N Bioeng Transl Med. 2025; 10(2):e10725.

PMID: 40060765 PMC: 11883116. DOI: 10.1002/btm2.10725.


Evaluating the anti-inflammatory and antioxidant efficacy of complementary and alternative medicines (CAM) used for management of inflammatory bowel disease: a comprehensive review.

Shin S, Chen S, Xie K, Duhun S, Ortiz-Cerda T Redox Rep. 2025; 30(1):2471737.

PMID: 40056427 PMC: 11892051. DOI: 10.1080/13510002.2025.2471737.


Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system.

Wang S, Wang X, Ding J, Zhang X, Zhu H, Fan Y Front Pharmacol. 2025; 16:1436183.

PMID: 40008128 PMC: 11851071. DOI: 10.3389/fphar.2025.1436183.


The association between perceived social support and self-management behaviors in adolescents and young adults with inflammatory bowel disease: the chain mediating role of basic psychological needs and anxiety/depression.

Zhu Y, Chen Y, Tang Y, Zhang X, Shen Q, Li F Front Psychol. 2025; 16:1483021.

PMID: 39973951 PMC: 11836826. DOI: 10.3389/fpsyg.2025.1483021.


References
1.
Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher P, Mascheretti S . Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002; 359(9318):1661-5. DOI: 10.1016/S0140-6736(02)08590-2. View

2.
GRYBOSKI J . Ulcerative colitis in children 10 years old or younger. J Pediatr Gastroenterol Nutr. 1993; 17(1):24-31. DOI: 10.1097/00005176-199307000-00004. View

3.
Jorgensen L, Fredholm L, Petersen P, Hey H, Munkholm P, Brandslund I . How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)?. Clin Chem Lab Med. 2005; 43(4):403-11. DOI: 10.1515/CCLM.2005.073. View

4.
von Roon A, Karamountzos L, Purkayastha S, Reese G, Darzi A, Teare J . Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102(4):803-13. DOI: 10.1111/j.1572-0241.2007.01126.x. View

5.
Yang C, Singh P, Singh H, Le M, El-Matary W . Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015; 41(11):1079-93. DOI: 10.1111/apt.13181. View